Jennison Associates LLC Autolus Therapeutics PLC Transaction History

Jennison Associates LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 10, 2019	SELL	$24.38 - $34.71 $2.61 Million - $3.71 Million	-106,971 Closed	0 $0
Q4 2018 Feb 06, 2019	SELL	$24.21 - $48.01 $295,821 - $586,634	-12,219 Reduced 10.25%	106,971 $3.51 Million
Q3 2018 Nov 08, 2018	BUY	$20.86 - $33.33 $19,754 - $31,563	947 Added 0.8%	119,190 $3.6 Million
Q2 2018 Aug 02, 2018	BUY	$25.0 - $27.75 $2.96 Million - $3.28 Million	118,243 New	118,243 $3.17 Million

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.